Originally published October 24 2005
Cardiologists say Pargluva diabetes drug raises the risk of death
by Mike Adams, the Health Ranger, NaturalNews Editor
The drug muraglitazar has been the subject of recent controversy, as several noted physicians have published a study in JAMA revealing the excess number of adverse coronary events in clinical trials that evaluated Bristol-Merck's Pargluva drug.
A new diabetes pill that appeared headed for federal approval can double the risk for deaths, heart attacks and strokes, according to an independent analysis rushed online yesterday because of public safety concerns.
The drug muraglitazar, developed by Bristol-Myers Squibb and Merck & Co. -- to be sold under the name Pargluva -- was endorsed by a Food and Drug Administration panel last month.
It is a treatment for Type 2 diabetes, the most common form of the condition that occurs most often in adults who are overweight.
All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing LLC takes sole responsibility for all content. Truth Publishing sells no hard products and earns no money from the recommendation of products. NaturalNews.com is presented for educational and commentary purposes only and should not be construed as professional advice from any licensed practitioner. Truth Publishing assumes no responsibility for the use or misuse of this material. For the full terms of usage of this material, visit www.NaturalNews.com/terms.shtml